Global private equity and venture capital news and research

Posts Tagged ‘biopharma’

19 June 2014

Polaris backs biopharmaceutical startup Navitor’s $23.5m Series A

navitor Biopharmaceutical company Navitor Pharmaceuticals has raised a $23.5m Series A round from venture capital backer.

8 April 2014

Lightstone Ventures secures more than $150m for debut fundp

life science test tube_sq Life sciences-focused venture capital firm Lightstone Ventures has passed the halfway mark for its debut fund, AltAssets has learned.

11 March 2014

Lumena Pharmaceuticals raises $45m in NEA-led Series B

biotech_lrg New Enterprise Associates led a $45m Series B round for biopharmaceutical company Lumena Pharmaceuticals, which is focused on developing products for rare cholestatic liver diseases and serious metabolic disorders.

7 February 2014

Eleven Biotherapeutics raises $50m via IPO

dollar envelope money Venture capital-backed biopharmaceutical company Eleven Biotherapeutics has raised $50m via an IPO on the Nasdaq exchange.

19 September 2013

Valuations in life sciences sector climb 15% in second quarterp

biotech_lrg Company valuations in the US life sciences sector increased at a slower pace in the second quarter compared to the first three months of the year, according to a recent report.

8 August 2013

Amkey Ventures leads $20m Series A1 for for biopharmaceutical company Apexigen

Amkey Ventures has led a $20m Series A round for biopharmaceutical startup Apexigen, which is developing antibody-based drugs for the treatment of life threatening and hard to treat diseases.

15 May 2013

Apple Tree and Novartis back Tokai’s $35m Series E

pharmaceutical 12_sq Cancer-focused biotech firm Tokai Pharmaceuticals has wrapped up a $35m Series E round, which was supported by existing investors Apple Tree Partners and Novartis Venture Funds.

18 July 2012

France’s Seventure Partners leads €2m round for Domain Therapeutics

Domain Therapeutics, a French biopharmaceutical company specialised in the research and early development of new drug candidates targeting G-Protein Coupled Receptors, has completed a €2m financing round led by new investor Seventure Partners.

7 June 2012

PhaseBio Pharmaceuticals raises $48.4m from NEA-backed Series B

PhaseBio, a clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, has raised $48.4m from a Series B financing round from existing investors including New Enterprise Associates.

23 April 2012

OrbiMed hits $220m close on first Israeli life sciences fund

Global healthcare investor OrbiMed has closed its first Israeli life sciences venture fund on $220m thanks to an anchor investment from the country’s government.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014